LTD High Technology Hospital Medcenter

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Lung cancer9 trials
• Endometrial cancer2 trials
• Melanoma2 trials
• Prostate cancer2 trials
• Bladder cancer1 trial
• Chronic kidney disease1 trial
• Colorectal cancer1 trial
• COPD1 trial
• Gastric and oesophageal cancer1 trial
• Head and neck cancer1 trial
• High blood pressure1 trial
• Kidney cancer1 trial
• and 4 more

Phase

• Phase 25 trials
• Phase 35 trials
• Phase 13 trials
• Phase 1/21 trial
• Phase 2/31 trial

Status

• Active, not recruiting9 trials
• Recruiting5 trials
• Terminated1 trial

Lead sponsor

• Regeneron Pharmaceuticals2 trials
• Amgen1 trial
• BicycleTx Limited1 trial
• Gilead Sciences1 trial
• IDEAYA Biosciences1 trial
• and 9 more

Running trials

• Recruiting

  REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

  NCT07410117· Phase 3· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Recruiting

  A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

  NCT07503808· Phase 1· IDEAYA Biosciences· Source

  Contact: Tamta Makharadze

• Active, not recruiting

  Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

  NCT07162883· Phase 3· Qilu Pharmaceutical Co., Ltd.· Source

• Active, not recruiting

  A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

  NCT07160335· Phase 1· Shanghai Henlius Biotech· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

  NCT06981078· Phase 2· Upstream Bio Inc.· Source

• Recruiting

  Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

  NCT07080242· Phase 1· SystImmune Inc.· Source

  Contact: Mamuka Sikharulidze

• Active, not recruiting

  Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

  NCT06225596· Phase 2· BicycleTx Limited· Source

• Active, not recruiting

  A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

  NCT06054555· Phase 3· Amgen· Source

• Recruiting

  Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

  NCT05797831· Phase 2/3· Kartos Therapeutics, Inc.· Source

  Contact: John Mei

• Active, not recruiting

  A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

  NCT05557591· Phase 2· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  Study With Various Immunotherapy Treatments in Participants With Lung Cancer

  NCT05676931· Phase 2· Gilead Sciences· Source

• Active, not recruiting

  THIO Sequenced With Cemiplimab in Advanced NSCLC

  NCT05208944· Phase 2· Maia Biotechnology· Source

• Recruiting

  Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

  NCT05098132· Phase 1/2· Synthekine· Source

• Active, not recruiting

  A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients

  NCT03390686· Phase 3· Prestige Biopharma Limited· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Endometrial cancer2 recruiting
• Prostate cancer2 recruiting
• Colorectal cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Neuroendocrine tumours1 recruiting
• Ovarian cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Terminated

  Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

  NCT04968184· Phase 3· Novo Nordisk A/S· Source